BNP Paribas Financial Markets Trims Stake in Dynavax Technologies Co. (NASDAQ:DVAX)

BNP Paribas Financial Markets lessened its holdings in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 45.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 32,737 shares of the biopharmaceutical company’s stock after selling 27,270 shares during the quarter. BNP Paribas Financial Markets’ holdings in Dynavax Technologies were worth $365,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of DVAX. Renaissance Technologies LLC increased its stake in shares of Dynavax Technologies by 2.2% in the second quarter. Renaissance Technologies LLC now owns 2,478,178 shares of the biopharmaceutical company’s stock worth $27,830,000 after purchasing an additional 53,600 shares in the last quarter. Great Point Partners LLC lifted its position in shares of Dynavax Technologies by 87.7% in the second quarter. Great Point Partners LLC now owns 2,374,000 shares of the biopharmaceutical company’s stock valued at $26,660,000 after acquiring an additional 1,109,080 shares in the last quarter. Millennium Management LLC bought a new position in shares of Dynavax Technologies in the second quarter worth about $17,615,000. Mizuho Markets Americas LLC boosted its stake in shares of Dynavax Technologies by 17.4% in the third quarter. Mizuho Markets Americas LLC now owns 1,379,582 shares of the biopharmaceutical company’s stock worth $15,369,000 after acquiring an additional 204,475 shares during the period. Finally, Bank of Montreal Can grew its position in shares of Dynavax Technologies by 8.3% during the third quarter. Bank of Montreal Can now owns 1,077,081 shares of the biopharmaceutical company’s stock worth $11,848,000 after purchasing an additional 82,449 shares in the last quarter. Institutional investors own 96.96% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $29.00 target price on shares of Dynavax Technologies in a report on Friday, November 8th.

Dynavax Technologies Price Performance

NASDAQ:DVAX opened at $12.96 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. The business has a 50 day simple moving average of $12.02 and a 200-day simple moving average of $11.48. The firm has a market capitalization of $1.70 billion, a price-to-earnings ratio of 99.70 and a beta of 1.33. Dynavax Technologies Co. has a 1 year low of $9.74 and a 1 year high of $15.01.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.